References
- Vernazza P, Hirschel B, Bernasconi E, et al. Les personnes séropositives ne souffrant d’aucuneautre MST et suivant un traitement antirétroviral efficacene transmettent pas le VIH par voie sexuelle. Bulletin Des Médecins Suisses. 2008;89(5):165–169.
- Cohen MS, Chen YQ, McCauley M, et al. Prevention of HIV-1 infection with early antiretroviral therapy. N Engl J Med. 2011;365(6):493–505.
- Albert J, Berglund T, Gisslen M, et al. Risk of HIV transmission from patients on antiretroviral therapy: a position statement from the Public Health Agency of Sweden and the Swedish Reference Group for Antiviral Therapy. Scand J Infect Dis. 2014;46(10):673–677.
- Bavinton BR, Pinto AN, Phanuphak N, et al. Viral suppression and HIV transmission in serodiscordant male couples: an international, prospective, observational, cohort study. Lancet Hiv. 2018;5(8):e438–e447.
- Rodger AJ, Cambiano V, Bruun T, et al. Sexual activity without condoms and risk of HIV transmission in serodifferent couples when the HIV-positive partner is using suppressive antiretroviral therapy. JAMA. 2016;316(2):171–181.
- Rodger AJ, Cambiano V, Bruun T, et al. Risk of HIV transmission through condomless sex in serodifferent gay couples with the HIV-positive partner taking suppressive antiretroviral therapy (PARTNER): final results of a multicentre, prospective, observational study. Lancet. 2019;393(10189):2428–2438.
- Fidler S, Anderson J, Azad Y, et al. Position statement on the use of antiretroviral therapy to reduce HIV transmission, January 2013: the British HIV Association (BHIVA) and the Expert Advisory Group on AIDS (EAGA). HIV Med. 2013;14(5):259–262.
- Folkhälsomyndigheten (Public Health Agency of Sweden). Preexpositionsprofylax för att minska risken för infektion med hiv, 2017; [cited 2020 Oct 1]. Available from: https://www.folkhalsomyndigheten.se/contentassets/749aa45e1c654336a7cd36b69ef08993/preexpositionsprofylax-minska-risken-infektion-hiv.pdf.
- RAV (Referensgruppen för antiviral terapi). HIV preexpositionsprofylax (PrEP) – Rekommendation om praktisk handläggning 2017, 2017; [cited 2020 Oct 1]. Available from:. https://www.sls.se/globalassets/rav/rekommendationer/rav_hiv_prep_2017_v170824.pdf.
- Eriksen J, Carlander C, Albert J, et al. Antiretroviral treatment for HIV infection: Swedish recommendations 2019. Infect Dis. 2020;52(5):295–329.
- Zeluf-Andersson G, Eriksson LE, Schonnesson LN, et al. Beyond viral suppression: the quality of life of people living with HIV in Sweden. AIDS Care. 2019;31(4):403–412.
- Folkhälsomyndigheten (Public Health Agency of Sweden). Att leva med hiv i Sverige – En studie om livskvalitet hos personer som lever med hiv, 2016; [cited 2020 Oct 1]. Available from:https://www.folkhalsomyndigheten.se/contentassets/bf0e69d28d714840a5e508f935d9956d/att-leva-hiv-sverige-studie-livskvalitet-16031-webb.pdf.
- Lohse N, Hansen AB, Pedersen G, et al. Survival of persons with and without HIV infection in Denmark, 1995-2005. Ann Intern Med. 2007;146(2):87–95.
- Antiretroviral Therapy Cohort C. Life expectancy of individuals on combination antiretroviral therapy in high-income countries: a collaborative analysis of 14 cohort studies. Lancet. 2008;372(9635):293–299.
- van Sighem AI, Gras LA, Reiss P, et al. Life expectancy of recently diagnosed asymptomatic HIV-infected patients approaches that of uninfected individuals. AIDS. 2010;24(10):1527–1535.
- Nakagawa F, Lodwick RK, Smith CJ, et al. Projected life expectancy of people with HIV according to timing of diagnosis. AIDS. 2012;26(3):335–343.
- Politch JA, Mayer KH, Welles SL, et al. Highly active antiretroviral therapy does not completely suppress HIV in semen of sexually active HIV-infected men who have sex with men. AIDS. 2012;26(12):1535–1543.
- Lambert-Niclot S, Tubiana R, Beaudoux C, et al. Detection of HIV-1 RNA in seminal plasma samples from treated patients with undetectable HIV-1 RNA in blood plasma on a 2002–2011 survey. AIDS. 2012;26(8):971–975.
- Wood E, Kerr T, Marshall BD, et al. Longitudinal community plasma HIV-1 RNA concentrations and incidence of HIV-1 among injecting drug users: prospective cohort study. BMJ. 2009;338(1):b1649–b1649.
- Kirk GD, Galai N, Astemborski J. Decline in community viral load strongly associated with declining HIV incidence among IDU. 8th Conference on Retroviruses and Opportunistic Infections. Boston, MA, USA, 2011.
- Fraser H, Mukandavire C, Martin NK, et al. HIV treatment as prevention among people who inject drugs – a re-evaluation of the evidence. Int J Epidemiol. 2017;46(2):466–478.
- RAV. Profylax och behandling av hivinfektion vid graviditet, Stockholm, Sweden: Referensgruppen för antiviral terapi (RAV), 2017; [cited 2020 Oct 1]. Available from: https://wwwslsse/globalassets/rav/rekommendationer/hiv_gravida_final_20180516pdf.
- Townsend CL, Cortina-Borja M, Peckham CS, et al. Low rates of mother-to-child transmission of HIV following effective pregnancy interventions in the United Kingdom and Ireland, 2000–2006. AIDS. 2008;22(8):973–981.
- WHO. Infant feeding for the prevention of mother-to-child transmission of HIV. Geneva, Switzerland: Organization WH, ed.; 2019.
- Health Protection Agency. Occupational transmission of HIV – Summary of Published Reports In: March 2005 Edition DtD, ed, 2005; [cited 2020 Oct 1]. Available from: https://webarchive.nationalarchives.gov.uk/20140714095709/http:/www.hpa.org.uk/webc/HPAwebFile/HPAweb_C/1194947320156.
- Joyce MP, Kuhar D, Brooks JT. Notes from the field: occupationally acquired HIV infection among health care workers – United States, 1985–2013. MMWR Morb Mortal Wkly Rep. 2015;63(53):1245–1246.
- Furtado MR, Callaway DS, Phair JP, et al. Persistence of HIV-1 transcription in peripheral-blood mononuclear cells in patients receiving potent antiretroviral therapy. N Engl J Med. 1999;340(21):1614–1622.
- Ibanez A, Puig T, Elias J, et al. Quantification of integrated and total HIV-1 DNA after long-term highly active antiretroviral therapy in HIV-1-infected patients. AIDS. 1999;13(9):1045–1049.
- Expert Advisory Group on AIDS (EAGA). EAGA guidance on HIV post-exposure prophylaxis. Recommendation for HIV post-exposure prophylaxis (PEP) following occupational exposure to a source with undetectable HIV viral load, 2013; [cited 2020 Oct 1]. Available from: https://www.gov.uk/government/publications/eaga-guidance-on-hiv-post-exposure-prophylaxis.
- Kuhar DT, Henderson DK, Struble KA, et al. Updated US Public Health Service guidelines for the management of occupational exposures to human immunodeficiency virus and recommendations for postexposure prophylaxis. Infect Control Hosp Epidemiol. 2013;34(9):875–892.
- European AIDS Clinical Society (EACS). GUIDELINES Version 9.1 201, 2018; [cited 2020 Oct 1]. Available from: https://www.eacsociety.org/files/2018_guidelines-9.1-english.pdf.